Riset dan Pengabdian Masyarakat
Do Research Sosial Service and Innovation
Publikasi Scopus 2025 per tanggal 31 Januari 2025 (67 artikel)
Publikasi Scopus 2025 per tanggal 31 Januari 2025 (67 artikel)
Nimkar, Smita (56820043000); Kinikar, Aarti (6506892585); Mave, Vidya (24778446900); Khol, Vohith (57188842644); Du, Quy Tuan (56405976400); Nguyen, Lam (56012339600); Ounchanum, Pradthana (57200558813); Nguyen, Dinh Qui (58581190800); Puthanakit, Thanyawee (8071686900); Kosalaraks, Pope (59348519500); Chokephaibulkit, Kulkanya (7003974471); Sudjaritruk, Tavitiya (36538198800); Muktiarti, Dina (57189047743); Kumarasamy, Nagalingeswaran (7003549856); Yusoff, Nik Khairulddin Nik (37027688000); Moh
Long-term risk of mortality and loss to follow-up in children and adolescents on antiretroviral therapy in Asia
2025
HIV Medicine
26
1
140
152
12
0
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85205282337&doi=10.1111%2fhiv.13718&partnerID=40&md5=771a7baddf3b58e21c6ab05a705d0e0b
B J Govt Medical College – Johns Hopkins University, Clinical Research Site, Pune, India; Department of Pediatrics, B J Govt Medical College and Sassoon General Hospitals, Pune, India; National Centre for HIV/AIDS, Dermatology and STDs, Phnom Penh, Cambodia; Infectious Diseases Department, Children's Hospital 1, Ho Chi Minh City, Viet Nam; Infectious Diseases Department, National Hospital of Pediatrics, Hanoi, Viet Nam; Department of Pediatrics, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; Infectious Disease Department, Children's Hospital 2, Ho Chi Minh City, Viet Nam; Department of Pediatrics and Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Division of Infectious Disease, Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Clinical and Molecular Epidemiology of Emerging and Re-emerging Infectious Diseases Research Cluster, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Faculty of Medicine, Dr. Cipto Mangunkusumo–Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; VHS-Infectious Diseases Medical Centre, Chennai, India; Department of Pediatrics, Hospital Raja Perempuan Zainab II, Kota Bharu, Malaysia; Department of Pediatrics, Women and Children Hospital Kuala Lumpur (WCHKL), Kuala Lumpur, Malaysia; Faculty of Medicine, Udayana University-Prof. Dr. I.G.N.G. Ngoerah Hospital, Bali, Indonesia; Faculty of Medicine, Hasan Sadikin General Hospital, Bandung, Indonesia; Department of Pediatrics, Hospital Likas, Kota Kinabalu, Malaysia; Department of Pediatrics Penang Hospital, Penang, Malaysia; TREAT Asia, amfAR – The Foundation for AIDS Research, Bangkok, Thailand; The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia
Objective: We described mortality and loss to follow-up (LTFU) in children and adolescents who were under care for more than 5 years following initiation of antiretroviral therapy (ART). Methods: Patients were followed from 5 years after ART until the earlier of their 25th birthday, last visit, death, or LTFU. We used Cox regression to assess predictors of mortality and competing risk regression to assess factors associated with LTFU. Results: In total, 4488 children and adolescents initiating ART between 1997 and 2016 were included in the analysis, with a median follow-up time of 5.2 years. Of these, 107 (2.2%) died and 271 (6.0%) were LTFU. Mortality rate was 4.35 and LTFU rate 11.01 per 1000 person-years. Increased mortality was associated with AIDS diagnosis (adjusted hazard ratio [aHR] 1.71; 95% confidence interval [CI] 1.24–2.37), current CD4 count <350 cells/mm3 compared with ≥500 (highest aHR 13.85; 95% CI 6.91–27.76 for CD4 <200), viral load ≥10 000 copies/mL compared with <400 (aHR 3.28; 95% CI 1.90–5.63), and exposure to more than one ART regimen (aHR 1.51; 95% CI 1.14–2.00). Factors associated with LTFU were male sex (adjusted subdistribution hazard ratio [asHR] 1.29; 95% CI 1.04–1.59), current viral load >1000 copies/mL compared with <400 (highest asHR 2.36; 95% CI 1.19–4.70 for viral load 1000–9999), and ART start after year 2005 compared with ≤2005 (highest asHR 5.96; 95% CI 1.98–17.91 for 2010–2016). Conclusion: For children and adolescents surviving 5 years on ART, both current CD4 and viral load remained strong indicators that help to keep track of their treatment outcomes. More effort should be made to monitor patients who switch treatments. © 2024 British HIV Association.
Adolescent; Anti-HIV Agents; Anti-Retroviral Agents; Asia; CD4 Lymphocyte Count; Child; Child, Preschool; Female; Follow-Up Studies; HIV Infections; Humans; Infant; Lost to Follow-Up; Male; Proportional Hazards Models; Risk Factors; Viral Load; CD4 antigen; anti human immunodeficiency virus agent; antiretrovirus agent; adolescent; antiretroviral therapy; Article; CD4 lymphocyte count; child; female; follow up; human; longitudinal study; major clinical study; male; mortality; mortality rate; risk factor; therapy effect; treatment outcome; virus load; Asia; drug therapy; epidemiology; Human immunodeficiency virus infection; infant; mortality; preschool child; proportional hazards model; risk factor
John Wiley and Sons Inc
14642662
39324422
Article
Q1
1052
4061